MapLight Therapeutics Initiates Phase 2 Study for Potential Alzheimer's Disease Psychosis Treatment

Strategic Insights -

MapLight Therapeutics has initiated a Phase 2 study to evaluate the efficacy, safety, and tolerability of ML-007C-MA, an investigational novel M1/M4 agonist, as a potential treatment for Alzheimer's disease psychosis (ADP). The study, known as the VISTA study, has been designed based on the results of an extensive Phase 1 development program that included 270 healthy volunteers, including 42 healthy elderly volunteers who received active drug. The company aims to address the significant unmet need for FDA-approved treatments for ADP, which can lead to poor patient outcomes due to the off-label use of antipsychotics.

Key Takeaways:

  • MapLight Therapeutics has initiated a Phase 2 study to evaluate the efficacy, safety, and tolerability of ML-007C-MA, a potential treatment for Alzheimer's disease psychosis (ADP).
  • The study, known as the VISTA study, is a randomized, double-blind, placebo-controlled trial that will enroll approximately 300 patients and evaluate the change in the Neuropsychiatric Inventory - Clinician Rating Scale Hallucinations and Delusions (NPI-C H+D) score from baseline to Week 7.
  • The Phase 2 study is designed based on the results of an extensive Phase 1 development program that included 270 healthy volunteers, including 42 healthy elderly volunteers who received active drug.
  • The company aims to address the significant unmet need for FDA-approved treatments for ADP, which can lead to poor patient outcomes due to the off-label use of antipsychotics.
  • Muscarinic receptor agonism has shown promising results as a therapeutic strategy for ADP, and the initiation of the VISTA study marks an important milestone in the development of ML-007C-MA.
  • ML-007C-MA has a favorable safety and tolerability profile, having achieved or exceeded levels of CNS exposure that are clinically relevant in healthy elderly volunteers in Phase 1.

Statistics:

  • 270 healthy volunteers participated in the Phase 1 development program.
  • 42 healthy elderly volunteers received active drug in the Phase 1 development program.
  • Approximately 300 patients will be enrolled in the Phase 2 VISTA study.
  • The primary endpoint of the study is the change in the NPI-C H+D score from baseline to Week 7.

Sources:

  • MapLight Therapeutics news release [Date not specified]
  • Interview with Christopher Kroeger, M.D., M.B.A., Chief Executive Officer and Founder of MapLight Therapeutics [Date not specified]
  • Interview with Erin Foff, M.D., Ph.D., Chief Medical Officer of MapLight Therapeutics [Date not specified]